GSK to sell US Wellbutrin XL rights to Biovail for $510 million
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to sell the US rights to its antidepressant Wellbutrin XL (bupropion hydrochloride extended-release tablets) to Biovail for $510 million.